Replication of PTPRC as genetic biomarker of response to TNF inhibitors in patients with rheumatoid arthritis

Pharmacogenomics Journal

Volumn 16, Issue 2, 2016, Pages 137-140

  Ferreiro Iglesias, A ^a   Montes, A ^a   Perez Pampin, E ^a   Canete J D ^b   Raya, E ^c   Magro Checa, C ^c   Vasilopoulos, Y ^d   Sarafidou, T ^d   Caliz, R ^e   Ferrer, M A ^e   Joven, B ^f   Carreira, P ^f   Balsa, A ^g   Pascual Salcedo, D ^h   Blanco, F J ^i,j   Moreno Ramos, M J ^k   Fernandez Nebro A ^l   Ordonez M C ^l   Alegre Sancho, J J ^m   Narvaez J ⁿ   Navarro Sarabia, F ^o   Moreira, V ^o   Valor, L ^p   Garcia Portales R ^q   Marquez, A ^r   Martin, J ^r   Gomez Reino J J ^a,j   Gonzalez, A ^a   more..

^a Santiago University Clinical Hospital   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^d UNIVERSITY OF THESSALY   (Greece)

^e HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^f HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^g HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^h HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

ⁱ HOSPITAL JUAN CANALEJO   (Spain)

^j UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^k HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^l UNIVERSITY OF MÁLAGA   (Spain)

^m HOSPITAL UNIVERSITARIO DR PESET   (Spain)

ⁿ HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^o HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^p HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^q HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^r INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; CD45 ANTIGEN; CHUK PROTEIN, HUMAN; GENETIC MARKER; I KAPPA B KINASE; INTERLEUKIN 10; PTPRC PROTEIN, HUMAN; TUMOR NECROSIS FACTOR;

ADULT; ALLELE; ARTICLE; CHUK GENE; DRUG RESPONSE; FEMALE; GENE; GENE LOCUS; GENE REPLICATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; IL10 GENE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PTPRC GENE; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; GENETIC ASSOCIATION STUDY; GENETIC MARKER; GENETICS; MIDDLE AGED; RISK;

ADALIMUMAB; ANTIGENS, CD45; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC MARKERS; HUMANS; I-KAPPA B KINASE; INFLIXIMAB; INTERLEUKIN-10; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84928151802     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2015.29     Document Type: Article

References (33)

1. Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014; 73: 492-509
2. Malottki K, Barton P, Tsourapas A, Uthman AO, Liu Z, Routh K et al. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation. Health Technol Assess 2011; 15: 1-278
3. Salliot C, Finckh A, Katchamart W, Lu Y, Sun Y, Bombardier C et al. Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional diseasemodifying antirheumatic drugs or to an antiTumour necrosis factor agent: a meta-nalysis. Ann Rheum Dis 2011; 70: 266-271
4. Emery P, Dorner T. Optimising treatment in rheumatoid arthritis: a review of potential biological markers of response. Ann Rheum Dis 2011; 70: 2063-2070
5. Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U et al. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Ann Rheum Dis 2011; 70: 1575-1580
6. Isaacs JD, Cohen SB, Emery P, Tak PP, Wang J, Lei G et al. Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-nalysis. Ann Rheum Dis 2013; 72: 329-336
7. Plant D, Wilson AG, Barton A. Genetic and epigenetic predictors of responsiveness to treatment in RA. Nat Rev Rheumatol 2014; 10: 329-337
8. Padyukov L, Lampa J, Heimburger M, Ernestam S, Cederholm T, Lundkvist I et al. Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis. Ann Rheum Dis 2003; 62: 526-529
9. Liu C, Batliwalla F, Li W, Lee A, Roubenoff R, Beckman E et al. Genome-wide association scan identifies candidate polymorphisms associated with differential response to antiTNF treatment in rheumatoid arthritis. Mol Med 2008; 14: 575-581
10. Cui J, Stahl EA, Saevarsdottir S, Miceli C, Diogo D, Trynka G et al. Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis. PLoS Genet 2013; 9: e1003394
11. Krintel SB, Palermo G, Johansen JS, Germer S, Essioux L, Benayed R et al. Investigation of single nucleotide polymorphisms and biological pathways associated with response to TNFalpha inhibitors in patients with rheumatoid arthritis. Pharmacogenet Genomics 2012; 22: 577-589
12. Plant D, Bowes J, Potter C, Hyrich KL, Morgan AW, Wilson AG et al. Genome-wide association study of genetic predictors of antiTumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci. Arthritis Rheum 2011; 63: 645-653
13. Umicevic Mirkov M, Cui J, Vermeulen SH, Stahl EA, Toonen EJ, Makkinje RR et al. Genome-wide association analysis of antiTNF drug response in patients with rheumatoid arthritis. Ann Rheum Dis 2013; 72: 1375-1381
14. Cui J, Saevarsdottir S, Thomson B, Padyukov L, van der Helm-van Mil AH, Nititham J et al. Rheumatoid arthritis risk allele PTPRC is also associated with response to antitumor necrosis factor alpha therapy. Arthritis Rheum 2010; 62: 1849-1861
15. Plant D, Prajapati R, Hyrich KL, Morgan AW, Wilson AG, Isaacs JD et al. Replication of association of the PTPRC gene with response to antiTumor necrosis factor therapy in a large UK cohort. Arthritis Rheum 2012; 64: 665-670
16. Prajapati R, Plant D, Morgan AW, Isaacs J, Wilson AG, BRAGGSS UK et al. Investigation of rheumatoid arthritis susceptibility genes identifies an association between TRAF6 with response to antiTumour necrosis factor-? therapy in a large UK cohort Annual EULAR Congress, 2011, London. Ann Rheum Dis 2011; 70: 145
17. Tan RJ, Gibbons LJ, Potter C, Hyrich KL, Morgan AW, Wilson AG et al. Investigation of rheumatoid arthritis susceptibility genes identifies association of AFF3 and CD226 variants with response to antiTumour necrosis factor treatment. Ann Rheum Dis 2010; 69: 1029-1035
18. Potter C, Cordell HJ, Barton A, Daly AK, Hyrich KL, Mann DA et al. Association between antiTumour necrosis factor treatment response and genetic variants within the TLR and NF{kappa}B signalling pathways. Ann Rheum Dis 2010; 69: 1315-1320
19. Coulthard LR, Taylor JC, Eyre S, Robinson JI, Wilson AG, Isaacs JD et al. Genetic variants within the MAP kinase signalling network and antiTNF treatment response in rheumatoid arthritis patients. Ann Rheum Dis 2011; 70: 98-103
20. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-324
21. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-48
22. Trynka G, Sandor C, Han B, Xu H, Stranger BE, Liu XS et al. Chromatin marks identify critical cell types for fine mapping complex trait variants. Nat Genet 2013; 45: 124-130
23. The 1000 Genomes Project Browser 2014 http://browser.1000genomes.org/index.html
24. van Gestel AM, Haagsma CJ, van Riel PL. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 1998; 41: 1845-1850
25. Montes A, Perez-Pampin E, Narvaez J, Canete JD, Navarro-Sarabia F, Moreira V et al. Association of FCGR2A with the response to infliximab treatment of patients with rheumatoid arthritis. Pharmacogenet Genomics 2014; 24: 238-245
26. Pappas DA, Oh C, Plenge RM, Kremer JM, Greenberg JD. Association of rheumatoid arthritis risk alleles with response to antiTNF biologics: results from the CORRONA registry and meta-nalysis. Inflammation 2013; 36: 279-284
27. Zervou MI, Myrthianou E, Flouri I, Plant D, Chlouverakis G, Castro-Giner F et al. Lack of association of variants previously associated with antiTNF medication response in rheumatoid arthritis patients: results from a homogeneous Greek population. PLoS One 2013; 8: e74375
28. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727-735
29. Royston P, Altman DG, Sauerbrei W. Dichotomizing continuous predictors in multiple regression: a bad idea. Stat Med 2006; 25: 127-141
30. Cooles FA, Isaacs JD, Anderson AE. Treg cells in rheumatoid arthritis: an update. Curr Rheumatol Rep 2013; 15: 352
31. Iyer SS, Cheng G. Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease. Crit Rev Immunol 2012; 32: 23-63
32. Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 1997; 24: 1-8
33. Larsson L, Johansson P, Jansson A, Donati M, Rymo L, Berglundh T. The Sp1 transcription factor binds to the G-llele of the-1087 IL-10 gene polymorphism and enhances transcriptional activation. Genes Immun 2009; 10: 280-284